These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24635127)

  • 1. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer.
    Blevins DP; Dadu R; Hu M; Baik C; Balachandran D; Ross W; Gunn B; Cabanillas ME
    Thyroid; 2014 May; 24(5):918-22. PubMed ID: 24635127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Aerodigestive fistula formation in antiangiogenic tyrosine kinase inhibitor therapy].
    Lorenz K; Dralle H
    Chirurg; 2014 Aug; 85(8):720. PubMed ID: 25070521
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiangiogenic TKIs and advanced RAI-resistant thyroid cancer: time for rethinking treatment strategies?
    Licitra L; Locati L
    Thyroid; 2014 Dec; 24(12):1815. PubMed ID: 25180537
    [No Abstract]   [Full Text] [Related]  

  • 4. Tracheoesophageal fistula development following radiotherapy and tyrosine kinase inhibitors in a patient with advanced follicular thyroid carcinoma: a case-based review.
    S Temperley T; Temperley HC; O'Sullivan NJ; Corr A; Brennan I; Kelly ME; Prior L
    Ir J Med Sci; 2024 Jun; 193(3):1143-1147. PubMed ID: 37922099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer.
    Lamartina L; Ippolito S; Danis M; Bidault F; Borget I; Berdelou A; Al Ghuzlan A; Hartl D; Blanchard P; Terroir M; Deandreis D; Schlumberger M; Baudin E; Leboulleux S
    J Clin Endocrinol Metab; 2016 Jul; 101(7):2733-41. PubMed ID: 27082933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
    Abdel-Rahman O; Fouad M
    Crit Rev Oncol Hematol; 2014 Dec; 92(3):194-207. PubMed ID: 25028151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
    Loriot Y; Boudou-Rouquette P; Billemont B; Ropert S; Goldwasser F
    Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel therapies for thyroid cancer.
    Krajewska J; Jarzab B
    Expert Opin Pharmacother; 2014 Dec; 15(18):2641-52. PubMed ID: 25318585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastropharyngeal Anastomotic Leak in Medullary Thyroid Carcinoma Following Initiation of a Tyrosine Kinase Inhibitor: A Case Report of an Unusual Side Effect of Cabozantinib.
    Ackerman J; Kent S; Walker P
    Ann Otol Rhinol Laryngol; 2020 Jul; 129(7):657-661. PubMed ID: 32037846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer.
    Gkountouvas A; Kostoglou-Athanassiou I; Veniou E; Repousis P; Ziras N; Kaldrimidis P
    Thyroid; 2010 Jun; 20(6):597-600. PubMed ID: 20553195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report.
    Kitamura M; Hayashi T; Suzuki C; Hirano S; Tateya I; Kishimoto Y; Omori K
    World J Surg Oncol; 2017 Jan; 15(1):24. PubMed ID: 28088233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
    Fagin JA; Tuttle RM; Pfister DG
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2621-4. PubMed ID: 20525911
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.
    Walraven M; Witteveen PO; Lolkema MP; van Hillegersberg R; Voest EE; Verheul HM
    Angiogenesis; 2011 May; 14(2):135-41. PubMed ID: 21188500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
    Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences.
    Chow H; Jung A; Talbott J; Lin AM; Daud AI; Coakley FV
    J Comput Assist Tomogr; 2011; 35(1):86-90. PubMed ID: 21245693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.